...
首页> 外文期刊>Journal of Clinical Imaging Science >Effects of Neoadjuvant Chemotherapy on Benign Breast Lesions Compared to Cancers: Should an Additional Lesion on Magnetic Resonance Imaging Responding Similar to Cancer after Neoadjuvant Chemotherapy be Viewed with Suspicion?
【24h】

Effects of Neoadjuvant Chemotherapy on Benign Breast Lesions Compared to Cancers: Should an Additional Lesion on Magnetic Resonance Imaging Responding Similar to Cancer after Neoadjuvant Chemotherapy be Viewed with Suspicion?

机译:Neoadjuvant化疗对良性乳腺病变的影响与癌症相比:在怀疑后,Neoadjuvant化疗后,磁共振成像的额外病变是否与癌症相似?

获取原文
           

摘要

Purpose: Determining the effects of neoadjuvant chemotherapy (NAC) on benign breast lesions and to evaluate their response in comparison to breast cancers. Methods: A retrospective analysis performed on breast cancer patients between 2008 and 2014 to identify patients who had a pre- and post-NAC magnetic resonance imaging (MRI) and biopsy-proven benign lesions. Pre- and post-NAC size and intensity of enhancement of benign lesions and cancers were measured. Breast glandularity and background enhancement were graded. A 2 × 2 repeated measures ANOVAs and Sidak post hoc tests were conducted for multiple comparisons. Paired t -tests were conducted to examine changes over time, and two-tailed P values were reported. Results: The effects of NAC in 38 cancers were compared to the effects of NAC in 47 benign lesions in these patients. From pre- to post-NAC, the mean size (cm) of malignant lesions on MRI decreased from 4.09 (±standard deviation [SD] 2.51) to 1.54 (±SD 2.32), ( P 0.001); the mean size (cm) of benign lesions decreased from 0.83 (±SD 0.54 cm) to 0.28 (±SD 0.51), ( P 0.001). Both benign and malignant lesions decreased in size after NAC, the size reduction in malignant lesions was significantly greater than benign lesions. From pre- to post-NAC, the mean lesion enhancement of the malignant lesions (scale 1–4) decreased from 3.43 (±SD 0.80) to 1.02 (±SD 1.34); the mean lesion enhancement of benign lesions decreased from 2.96 (±SD 1.04) to 0.98 (±SD 1.51). For both benign and malignant lesions, there was a significant overall reduction in enhancement after NAC from moderate at pre-NAC to minimal at post-NAC, P 0.001. There was no overall difference in the enhancement of cancers (mean = 2.22, SD = 0.79) versus benign lesions (mean = 1.97, SD = 1.08), ( P = 0.23). There was no significant change in glandularity from pretherapy (mean = 3.11, SD = 0.84) to posttherapy (mean = 3.13, SD = 0.82), P 0.001. Conclusion: Similar to cancers, benign breast lesions also show a significant decrease in size and enhancement after NAC; however, the decrease in size is less compared to cancers.
机译:目的:确定Neoadjuvant化疗(NAC)对良性乳腺病变的影响,并与乳腺癌相比评估它们的反应。方法:对2008年至2014年乳腺癌患者进行的回顾性分析,鉴定患有NAC后和NAC磁共振成像(MRI)和活检的良性病变的患者。测量了NAC后和良性病变和癌症的增强强度。乳腺腺体和背景增强分级。进行2×2重复测量ANOVAS和SIDAK后HOC测试进行多种比较。进行配对的T终点以随着时间的推移检查变化,并报告了双尾的P值。结果:将NAC在38例癌症中的影响与NAC在47例良性病变中的影响进行了比较。从NAC前,MRI对恶性病变的平均尺寸(CM)从4.09(标准偏差[SD] 2.51)降低至1.54(±SD 2.32),(P <0.001);良性病变的平均尺寸(cm)从0.83(±Sd 0.54cm)降至0.28(±SD 0.51),(P <0.001)。 NAC后良性和恶性病变均尺寸下降,恶性病变的大小明显大于良性病变。从NAC前,恶性病变的平均病变增强(SCALE 1-4)从3.43(±SD 0.80)降低至1.02(±SD 1.34);良性病变的平均病变增强从2.96(±SD 1.04)降低到0.98(±SD 1.51)。对于良性和恶性病变来说,NAC在NAC前NAC中的中度在NAC中的中等后,增强的显着整体降低了P <0.001。癌症的增强没有总体差异(平均值= 2.22,SD = 0.79),与良性病变(平均值= 1.97,SD = 1.08),(P = 0.23)。从去颈治疗(平均= 3.11,SD = 0.84)没有显着变化(平均= 3.11,SD = 0.84)(平均= 3.13,SD = 0.82),P <0.001。结论:与癌症类似,良性乳腺病变也显示出NAC后大小和增强的显着降低;然而,与癌症相比,尺寸的减少较少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号